IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/309% above fair value
$31.83+0.34 (+1.08%)
Close on Nov 13, 2026Market cap $3.07BP/E –Yield –
IDEAYA Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
IDEAYA Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -92.7%. For fiscal 2025 it was -72.8%, against -4671.1% the year before. The highest annual figure on record is -72.8% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -72.8% | +4598.2 |
| FY2024 | Dec 31, 2024 | -4671.1% | −4096.2 |
| FY2023 | Dec 31, 2023 | -574.9% | −452.1 |
| FY2022 | Dec 31, 2022 | -122.7% | +57.2 |
| FY2021 | Dec 31, 2021 | -179.9% | +1.0 |
| FY2020 | Dec 31, 2020 | -180.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1380.7% | +678.4 |
| Q1 FY2026 | Mar 31, 2026 | -1654.6% | −585.9 |
| Q4 FY2025 | Dec 31, 2025 | -869.5% | −452.4 |
| Q3 FY2025 | Sep 30, 2025 | 52.2% | +975.1 |
| Q4 FY2024 | Dec 31, 2024 | -2059.1% | −1725.6 |
| Q4 FY2023 | Dec 31, 2023 | -1068.8% | −411.3 |
| Q3 FY2023 | Sep 30, 2023 | -417.1% | −419.3 |
| Q2 FY2023 | Jun 30, 2023 | -922.9% | −538.4 |
| Q1 FY2023 | Mar 31, 2023 | -333.5% | −208.3 |
| Q4 FY2022 | Dec 31, 2022 | -657.5% | −37.3 |
| Q3 FY2022 | Sep 30, 2022 | 2.2% | +132.7 |
| Q2 FY2022 | Jun 30, 2022 | -384.5% | −258.3 |
| Q1 FY2022 | Mar 31, 2022 | -125.2% | +0.9 |
| Q4 FY2021 | Dec 31, 2021 | -620.2% | −570.2 |
| Q3 FY2021 | Sep 30, 2021 | -130.5% | −74.8 |
| Q2 FY2021 | Jun 30, 2021 | -126.2% | – |
| Q1 FY2021 | Mar 31, 2021 | -126.1% | – |
| Q4 FY2020 | Dec 31, 2020 | -49.9% | – |
| Q3 FY2020 | Sep 30, 2020 | -55.7% | – |
See a number that looks wrong?